Legal & General Group Plc grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,968,450 shares of the medical research company’s stock after buying an additional 41,041 shares during the period. Legal & General Group Plc owned approximately 0.49% of Thermo Fisher Scientific worth $372,405,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock worth $4,640,970,000 after purchasing an additional 629,093 shares during the period. BlackRock Inc. boosted its stake in Thermo Fisher Scientific by 1.6% in the 2nd quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock worth $4,074,828,000 after purchasing an additional 366,584 shares during the period. Capital Research Global Investors boosted its stake in Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after purchasing an additional 3,973,136 shares during the period. Capital World Investors boosted its stake in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after purchasing an additional 671,637 shares during the period. Finally, Morgan Stanley boosted its stake in Thermo Fisher Scientific by 7.6% in the 1st quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock worth $716,526,000 after purchasing an additional 327,826 shares during the period. 86.16% of the stock is owned by institutional investors.
Shares of Thermo Fisher Scientific Inc. (NYSE TMO) remained flat at $$189.49 during mid-day trading on Wednesday. 1,301,400 shares of the stock traded hands, compared to its average volume of 1,563,304. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. The company has a market capitalization of $75,984.62, a P/E ratio of 20.82, a PEG ratio of 1.74 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 52-week low of $139.88 and a 52-week high of $201.20.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is 10.19%.
A number of equities analysts recently weighed in on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a research note on Thursday, September 7th. Leerink Swann restated an “outperform” rating and set a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley restated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $205.21.
In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc. (TMO) Shares Bought by Legal & General Group Plc” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://weekherald.com/2017/12/13/thermo-fisher-scientific-inc-tmo-shares-bought-by-legal-general-group-plc.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.